Compass Therapeutics (CMPX) Accumulated Expenses (2019 - 2026)

Compass Therapeutics' Accumulated Expenses history runs 8 years deep, the most recent figure standing at $1.2 million for Q1 2026.

• In Q1 2026, Accumulated Expenses fell 20.58% year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at $1.2 million (down 20.58% YoY), while the FY2025 annual figure was $11.4 million, up 307.55% from the prior year.
• Accumulated Expenses came in at $1.2 million for Q1 2026 at Compass Therapeutics, down from $11.4 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $11.7 million in Q4 2022 to a low of $490000.0 in Q1 2022.
• A 5-year average of $3.4 million and a median of $2.0 million in 2025 frame the typical range for Accumulated Expenses.
• On a YoY basis, Accumulated Expenses climbed as much as 826.27% in 2023 and fell as far as 83.42% in 2023.
• Compass Therapeutics' Accumulated Expenses stood at $11.7 million in 2022, then sank by 83.42% to $1.9 million in 2023, then soared by 44.12% to $2.8 million in 2024, then soared by 307.55% to $11.4 million in 2025, then slumped by 89.59% to $1.2 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $1.2 million, $11.4 million, and $2.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison